Fast Market Research

Just Released: "OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018"

Recently published research from GlobalData, "OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018", is now available at Fast Market Research


Boston, MA -- (SBWIRE) -- 07/10/2014 -- Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease-modifying solution. However, isotretinoin is unable to serve a significant proportion of the acne market owed to its teratogenic nature, making its prescription for women of child-bearing age problematic.

In the past decade, there has been a shift in the acne market, with greater appreciation of its patient pool and potential for a lucrative payoff. Furthermore, there has been greater stress put on the social and psychological implications of the disease, which impact patients' quality of life. As a result, R&D investments have been initiated by key pharmaceutical players.
Key strategies underway in the acne market include -

View Full Report Details and Table of Contents

- Drive for combination therapies, for example, Galderma's Epiduo (adapalene and benzoyl peroxide), which continues to experience rapid uptake.
- Expansion of the market into the pediatric population and for late-onset acne in women.
- A push towards disease-modifying therapies; for example, launch of AndroScience's ASC-J9 androgen receptor degradation enhancer is anticipated to be a game-changer and is expected to rival isotretinoin, the current market leader for severe acne.


Key Questions Answered

- How will the US and 5EU acne markets evolve over the forecast period from 2012 to 2018 in terms of sales and patient numbers?
- How will the launch of late-stage pipeline therapies such as ASC-J9 and Visonac shape the future treatment landscape?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
- Why has there been a void of R&D interest from Big Pharma in this highly populated dermatology indication?
- What are the remaining unmet needs and opportunities for drug developers within the acne space?

Key Findings

- The main drivers of growth in the acne market during the 2012-2018 forecast period include the launch of AndroScience's ASC-J9, a therapeutic that is highly anticipated in the previously stagnant acne market and will make hormonal therapies available to males with acne, the continued success and uptake of Galderma's Epiduo, and the launch of Photocure's Visonac; potentially the first photodynamic therapy for use in acne.
- The lack of dedicated R&D programs in acne has been attributed to pharmaceutical companies viewing topicals, the mainstay of acne therapy, as being inexpensive, with a poor return on investment. Instead, R&D strategies have centered on reformulations of existing products and/or fixed-dose combination therapies, acquisitions of key dermatology products by Big Pharma, and label expansions into the previously untapped pediatric market. Targeting the pediatric market is a strategy that GlobalData expects will be used by other dermatology companies during the coming decade.
- A continued unmet need for acne is the need for new and innovative products to treat the underlying condition. Ideally, these products should be molecules that can specifically target critical pathways in the acne pathophysiology. Given the acne market's substantial patient pool (estimated to be 103.9 million patients in the US and 5EU) and increasing understanding of the disease's pathophysiology, GlobalData expects continued interest in the acne market from biotechs and pharmaceutical companies over the coming decade.


- Overview of acne, including epidemiology, etiology, pathophysiology, symptoms, and current treatment options.
- Annualized acne prescription therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2018.
- Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and benchmarking analysis for the acne prescription therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. Accompanied by an interactive clinical and commercial benchmarking analysis tool.
- Analysis of the current and future market competition in the US and 5EU acne prescription therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018
- OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017